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ABSTRACT 
Aims: Percutaneous pulmonary valve implantation (PPVI) has proven good hemodynamic 
results. As infective endocarditis (IE) remains a potential complication with limited available 
clinical data, we reviewed our patient records to improve future strategies of IE prevention, 
diagnosis and treatment.  
Methods: Medical records of all patients diagnosed with Melody® valve IE according to the 
modified Duke criteria were retrospectively analyzed in three Belgian tertiary centers.  
Results: 23 IE episodes in 22 out of 240 patients were identified (incidence 2.4% / patient 
year) with a clear male predominance (86%). Median age at IE was 17.9 years (range 8.2-
45.9 years) and median time from PPVI to IE was 2.4 years (range 0.7-8 years). 
Streptococcal species caused 10 infections (43%), followed by Staphylococcus aureus (n=5, 
22%). In 13/23 IE episodes a possible entry-point was identified (57%). IE was classified as 
definite in 15 (65%) and as possible in 8 (35%) cases due to limitations of imaging. 
Echocardiography visualized vegetations in only 10 patients. PET-CT showed positive FDG 
signals in 5/7 patients (71%) and intracardiac echocardiography a vegetation in 1/1 patient 
(100%). Eleven cases (48%) had a hemodynamically relevant pulmonary stenosis at IE 
presentation. Nine early and 6 late percutaneous or surgical re-interventions were performed. 
No IE related deaths occurred. 
Conclusions: IE after Melody® valve PPVI is associated with a relevant need of re-
interventions. Communication to patients and physicians about risk factors is essential in 
prevention. The modified Duke criteria underperformed in diagnosing definite IE, but 
inclusion of new imaging modalities might improve diagnostic performance. 
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ABSTRACT 
Aims: Percutaneous pulmonary valve implantation (PPVI) has proven good hemodynamic 
results. As infective endocarditis (IE) remains a potential complication with limited available 
clinical data, we reviewed our patient records to improve future strategies of IE prevention, 
diagnosis and treatment.  
Methods: Medical records of all patients diagnosed with Melody® valve IE according to the 
modified Duke criteria were retrospectively analyzed in three Belgian tertiary centers.  
Results: 23 IE episodes in 22 out of 240 patients were identified (incidence 2.4% / patient 
year) with a clear male predominance (86%). Median age at IE was 17.9 years (range 8.2-
45.9 years) and median time from PPVI to IE was 2.4 years (range 0.7-8 years). 
Streptococcal species caused 10 infections (43%), followed by Staphylococcus aureus (n=5, 
22%). In 13/23 IE episodes a possible entry-point was identified (57%). IE was classified as 
definite in 15 (65%) and as possible in 8 (35%) cases due to limitations of imaging. 
Echocardiography visualized vegetations in only 10 patients. PET-CT showed positive FDG 
signals in 5/7 patients (71%) and intracardiac echocardiography a vegetation in 1/1 patient 
(100%). Eleven cases (48%) had a hemodynamically relevant pulmonary stenosis at IE 
presentation. Nine early and 6 late percutaneous or surgical re-interventions were performed. 
No IE related deaths occurred. 
Conclusions: IE after Melody® valve PPVI is associated with a relevant need of re-
interventions. Communication to patients and physicians about risk factors is essential in 
prevention. The modified Duke criteria underperformed in diagnosing definite IE, but 
inclusion of new imaging modalities might improve diagnostic performance. 
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 ABBREVIATION LIST 
 
CHD  congenital heart disease 
BJV  bovine jugular vein 
IE  infective endocarditis 
PPVI  percutaneous pulmonary valve implantation 
RVOT  right ventricular outflow tract 
TEE  transesophageal echocardiography 
TTE  transthoracic echocardiography 
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INTRODUCTION 
Percutaneous pulmonary valve implantation (PPVI) using the Melody® valve (Medtronic Inc., 
Minneapolis, MN, US) has proven good technical feasibility and excellent hemodynamic 
results for right ventricular outflow tract (RVOT) valve replacement (1-3). Infective 
endocarditis (IE) however is emerging as an important challenge after PPVI causing 
considerable morbidity and need for re-interventions (4, 5). Recent studies state that the risk 
of developing IE seems to be higher after Melody® valve PPVI compared to surgical 
homograft implantation (6, 7). Incidences of about 3.2 – 12.9% are described in mid- to long-
term follow-up studies, versus 2% in surgical groups (3, 4, 8-10).   
Streptococcus and Staphylococcus species are the most frequent causative agents, but 
many other microorganisms have been reported (4, 11). Changes in IE epidemiology are of 
major interest after the guidelines for IE prophylaxis have been restricted from 2007 onwards 
(12). S. aureus infections are becoming more frequent due to an increase of medical 
procedures and subsequent hospitalization while Streptococci remain the most relevant 
underlying cause of community acquired IE (13, 14).  
Despite advances in medical treatment, IE diagnosis remains challenging and is frequently 
delayed. PPVI IE often presents late and is subacute in onset rather than peri-procedural, 
and clinical symptoms are variable and non-specific (4, 5, 13). Clinical IE presentations raise 
the question on specific predictors and risk factors for PPVI IE while data on the subject are 
still limited.  
IE diagnosis is based on the modified Duke criteria, by which a definite diagnosis is made 
mainly on the presence of multiple positive blood cultures and positive imaging for IE. The 
Duke criteria are characterized by a sensitivity of 70-80%, but have proven to be less 
accurate in the detection of prosthetic valve IE (12). 
Therefore, this study aims to investigate the clinical and epidemiological findings in all IE 
patients after Melody® valve implantation in three Belgian centers to improve future 
strategies of IE diagnosis, treatment and prevention in this patient group. In addition, we 
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focused on a critical evaluation of the role of the modified Duke criteria in diagnosing IE after 
Melody® valve PPVI. 
 
METHODS 
Patients 
A multi-center retrospective, observational study was performed by analyzing the Melody® 
valve registry from 1/1/2006 – 1/6/2017. Pediatric and adult patients who presented with IE 
after Melody® valve implantation in the RVOT in three Belgian tertiary referral centers, 
namely University Hospitals (UZ) Leuven, UZ Ghent and University Hospital Brussels Saint-
Luc (UCL), were identified and clinical data were reviewed. Interventional Melody® valve 
implantation was performed according to the standard protocol provided by the company. 
Details are described in the supplementary data. The study complies with the Declaration of 
Helsinki. Informed consent was taken from all patients or parents and data analysis was 
approved by the local ethic committees. 
 
Clinical IE data  
We gathered general demographic data, data on health history, underlying diagnosis and 
valve implantation. Data on clinical presentation and diagnosis of IE included predisposing 
factors, echocardiographic findings, biochemical data, underlying microorganisms, medical 
and surgical treatment, length of hospitalization, complications and outcome. IE was 
diagnosed according to the modified Duke criteria and all criteria were recorded and critically 
evaluated for their presence (12, 15). Diagnostic testing and antibiotic treatment was 
performed according to the ESC guidelines (detailed protocol in Supplementary Data) (12). 
Transcatheter or surgical treatment required within 3 months after IE presentation were 
defined as early interventions and after more than 3 months as late interventions. A detailed 
definition is given in the supplementary data.   
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Statistical analysis 
Continuous variables are reported as median ± range. Categorical variables are mentioned 
as frequencies and percentages of the specific group. Statistical analysis of group 
comparisons were performed by application of the Fischer´s exact test, the Pearson's χ2 test 
and the independent sample T-test. Annualized rates of IE were calculated using the total 
period of patient follow-up until diagnosis of IE or end point of the study period. Potential risk 
factors for IE with a calculated p-value of < 0.1 were further analyzed by a multivariate Cox 
regression analyses. Hazard ratios (HRs) and incidence rates were demonstrated with the 
95% confidence intervals (CIs). Statistical analysis was performed using GraphPad Prism 
(7.0d; GraphPad Software, San Diego California USA) and IBM SPSS Statistics 26 (IBM, 
New York, New York, USA).  
 
RESULTS 
Patients  
Twenty-three cases of possible and definite IE after Melody® valve implantation were 
identified in 22 patients according to the modified Duke criteria. A total of 240 patients (158 
male, 66%; and 82 female, 34%) who underwent Melody® valve implantation between 
1/1/2006 and 1/6/2017 were observed for 939.5 patient years in the study period. We report 
an overall IE incidence of 9.2% and an incidence of 2.4% / patient year: 16 out of 165 
patients in UZ Leuven, 3 out of 27 in UZ Ghent and 3 out of 48 in UCL (Figure 1A). The 
median age at IE occurrence was 17.9 years (range 8.2 - 45.9 years) and IE onset was 
reported at a median of 2.4 years (range 0.7 - 8.0 years) after valve implantation. There was 
a male predominance, as 19/22 IE patients were male (86%). The IE incidence in male 
patients was significantly higher compared to female patients (P value 0.03). Twelve percent 
(19 out of 158) of all male Melody® patients or 3.0% / patient year developed IE compared to 
3.7% (3 out of 82) of all female patients with an implanted Melody® stent or 0.9% / patient 
year. The male gender has been identified as an independent risk factor for developing IE 
(Table 1, HR 3.60).  
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One patient had an epicardial pacemaker implanted. Three patients were taking aspirin at 
the time of infection for prevention of thromboembolic events. In 2 patients, aspirin was 
prescribed at discharge from UZ Ghent and in 1 patient aspirin intake was not related to 
Melody® valve implantation. All but one patient underwent regular follow-up in each center at 
1, 3, 6 and 12 months after implantation and thereafter yearly. Further patient characteristics 
are summarized in Table 1.   
 
Clinical presentation of IE 
Fever was the major presenting symptom in 17 patients. Three additional patients described 
sub-febrile symptoms. When fever was absent, patients complained of effort intolerance and 
/ or general malaise. Four patients developed sepsis which turned into septic shock in 1 
patient. The causative microorganism in these 4 patients were S. aureus (n=3) and H. 
parainfluenza (n=1). One patient presented with peripheral edema due to right heart failure. 
Data on IE presentation are shown in Table 2. Results on the time point of diagnosis and 
predisposing factors are found in the Supplementary Data.  
 
Microbiology  
An underlying microorganism could be identified in the blood culture in all but 1 patient. 
Viridans group streptococci were the most frequent cause of IE (n=10), followed by S. aureus 
(n=5). Cultures remained negative after oral antibiotic treatment of episodic fever in 1 patient.  
In 4/5 patients with a S. aureus infection and 1/2 patients with a CNS infection a possible 
cutaneous entry-point could be identified. A viridans group streptococcus infection was 
associated with a dental predisposing factor in 5/10 patients. Figure 1B shows the causative 
microorganisms. 
 
Diagnosis of IE according to the modified Duke criteria  
Fifteen cases of IE were classified as definite and 8 cases as possible IE according to the 
modified Duke criteria (15). Table 3 shows the results for each of the detailed criteria. A 
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minimum of 3 blood cultures were taken before the start of antibiotics and the majority of 
patients had 2-5 positive cultures (17 episodes). In 5 patients only 1 blood culture turned out 
positive and in one the cultures remained negative. 
In 5 patients requiring an early valve explantation, additionally a histopathological (n=2) or 
molecular microbiological investigation (pan-bacterial PCR, n=3) was performed.  The PCR 
on tissue explants verified the underlying bacteria already identified in the blood culture in all 
patients: S. aureus in 2 patients and H. influenza in 1 patient. The histopathological findings 
showed a fibrin rich, purulent inflammation, confirming IE diagnosis. In 3 of the 5 patients, 
histopathological (n=2) or bacterial PCR examination (n=1) of the explanted Melody® valve 
contributed to the diagnosis of definite IE.  
Transthoracic echocardiographic (TTE) evaluation, including assessment of the gradient 
across the infected valve, was performed in all patients at the time of IE diagnosis and 
results are summarized in Supplementary Figure 1. Vegetations on TTE were seen in 9 
patients. Eleven patients received a transesophageal echocardiography (TEE) of which 7 
presented with an initially negative TTE. Importantly, TEE could only visualise a vegetation in 
one patient, in which it had not been seen by TTE before. In 4 patients TEE verified the 
vegetation known from TTE and TEE remained negative in the 6 other patients. Eleven 
patients developed a moderate or severe pulmonary stenosis (PS PIG > 40 mmHg or PS 
PIG > 60 mmHg, respectively, Table 2, Supplementary Data and Supplementary Figure 1 A 
and B). Seven of these 11 patients required an early transcatheter or surgical treatment.  
Imaging by PET-CT was performed in 7 patients and revealed positive signs (increased 
FDG-captation) in 5 of them at the Melody® valve. In 3 of these 5 patients vegetations were 
seen on TTE or TEE at the Melody® valve. Intracardiac echography was performed in 1 
patient and could clearly visualize the vegetation. None of the patients had concomitant 
involvement of the left heart valves or other locations besides the Melody® valve.  
 
Treatment and outcome 
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All patients received 6 weeks of antibiotic treatment according to the ESC guidelines (12). 
Thirteen of 22 patients (59%) required an RVOT intervention early or late after the IE episode 
due to the development of a stenosis of the Melody® valve. Supplementary Picture 1 shows 
an explanted Melody© valve infected by S. aureus. Two patients required urgent RVOT stent 
placement 1 day after presentation. Four patients underwent homograft implantation having 
an early elective surgical procedure after 9, 16, 18 and 32 days. In 2 additional patients a 
delayed homograft implantation was performed after 48 and 63 days. One patient underwent 
a delayed percutaneous balloon valvuloplasty after 51 days.  
A late intervention was performed in 6 patients. The 2 patients with an urgent RVOT stent 
placement received a Melody® and a Sapien® valve 3 and 10 months later. Three additional 
patients underwent RVOT valve replacement after more than 2 years (a Melody® valve, 
Sapien® valve and homograft in 1 patient each). Data are shown in Table 4. Detailed data on 
treatment and outcome comparing the IE cases treated medically and those who required an 
interventional treatment are summarized in the Supplementary Data and Supplementary 
Table 1.  
No deaths related to IE were seen. During follow-up 1 patient died after a status epilepticus, 
unrelated to IE.  
 
DISCUSSION 
IE remains a diagnostic and therapeutic challenge in patients after PPVI (5, 8, 13). After 
reviewing records of patients presenting with Melody® valve IE in three Belgian tertiary 
referral centers, our data clearly show a relatively high incidence of IE (2.4% / patient year) 
after a median time period of 2.4 years with a distinct male predomination of 86%. Viridans 
group streptococci accounted for 10/23 infections, followed by S. aureus (n=5). The course 
and outcome of the infection were mostly favorable and no deaths occurred related to IE. 
However, we saw a high rate of RVOT re-interventions. Early re-interventions were more 
frequent with IE caused by S. aureus or HACEK-group organisms and in the presence of 
pulmonary septic emboli.  
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Clinical presentation and outcome 
Several clinical observations support our documented high incidence of IE after PPVI of 3.2 
to 12.8% of patients (3-5, 8, 16). The same annual incidence of 2.4% / patient year for 
Melody® related IE was recently described (17).  Being male was associated with a higher 
risk to develop IE and identified as an independent risk factor. The IE incidence was 
significantly higher in male (3.0% / patient year) compared to female patients after Melody® 
valve implantation (0.9% / patient year). The gender difference can partly be explained by the 
higher incidence of CHD in men (17, 18). In our centers, 67-78% of all patients who had a 
Melody® valve implanted were male (2). A male predominance is also known in adult 
patients with IE of a percutaneous implanted aortic valve which could be partially associated 
with a potential endothelial protection via estrogen in females (19). In contrast to the findings 
of McElhinney et.al., in our cohort a younger age (<12y) at PPVI was not associated with an 
increased risk of IE or a higher rate of IE associated valve explantations (17).    
All IE cases in this study were late and community-acquired with a minimum period of 8 
months from implantation to IE development, and seem therefore not to be procedure 
related, as described by others (1, 8, 11, 18).  
IE of the Melody® valve caused by viridans group streptococci were most dominant in our 
series being responsible for 43% of cases versus 30% in other studies, in which 
staphylococci are the most prevalent species (47%) (5, 8, 17). 
Our data further reveal that Melody® IE presents clinically severe in distinct cases with 4 
patients having developed sepsis and 1 patient right-sided heart failure. In addition, clinical 
presentation with severe RVOT obstruction is frequent as seen in 7/23 cases (30%). These 
severe presentations are relevant in clinical practice, which is also supported by others 
reporting about 30% of patients presenting in emergency situations as sepsis, shock or 
severe right ventricular dysfunction and 34% with a RVOT gradient of > 60 mmHg (4, 8, 18). 
This has led to the attempt to categorize patients upon the clinical severity of IE presentation 
in order to enable a more accurate diagnosis and adequate treatment of IE (17).  
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RVOT re-intervention is frequently required after Melody® valve IE (13/22 patients, 59%) and 
our data are comparable to other reports which documented re-interventions in about 60% 
(1, 3, 5, 17). The indication and timing for an invasive treatment remain challenging. Criteria 
leading to the choice of re-intervention are not clearly defined yet and may depend on the 
severity of IE as well as on the experience of each center. Transcatheter treatment has 
proven to be effective and safe in 6/22 (27%) of our patients compared to 13-14% of IE 
patients in other reviews (3, 18). It has mainly a role in the treatment of critically ill patients 
presenting with severe RVOT obstruction where is leads to an acute decrease of the RVOT 
gradient and hemodynamical stabilization of the patient (2 patients in our study) (4, 10, 17).  
In semi-urgent cases, decision making favored a surgical implantation of a homograft in 
patients without other contraindications for an operative treatment in our centers (7/22 
patients) which is comparable with 43-48% Melody® valve explantations in other reports (3, 
18). In further studies, some cases are reported where interventional treatment has been 
performed as the primary and definite invasive treatment with a good result (4, 11, 17). 
Longtime follow-up studies need to evaluate the hemodynamic results and the risk of re-
infection post re-intervention for IE. A focus on determinants for decision making concerning 
the need of invasive IE treatment and the choice on intervention or surgery would support 
best patients’ outcome.  
Our study however shows no deaths related to IE, whereas a mortality rate up to 10% is 
described (4, 11). Importantly, S. aureus IE accounts for 80-90% of the patients with fatal 
outcome and is associated with a high need for re-interventions (11).    
 
Diagnosis and modified Duke criteria 
Questions have been raised whether the modified Duke criteria are sensitive enough to 
make a definite diagnosis of IE after PPVI as up to 38% of patients are classified as possible 
IE   (3, 17, 18, 20). Also in our study, the number of definite diagnoses of IE was lower than 
expected, namely 15/23 cases. A negative imaging for IE is leading to a major limitation of 
the Duke criteria and accounted for the classification as possible IE in all 8 patients.  In 
Jo
urn
al 
Pr
e-p
roo
f
Journal Pre-proof
general, imaging often fails to demonstrate vegetations, being positive for IE in just over half 
of our cases. The presence of prosthetic material in the anterior positioned RVOT hampers 
the visualization of vegetations on the Melody® valve.  
The sensitivity of TTE for detecting vegetations in prosthetic IE is variable with 36-69%, 
whereas TEE shows a higher sensitivity of 86-94% (21). Our data support the diagnostic 
limitation of repeated TTE and TEE, as in only less than 50% of the episodes a vegetation 
could be detected (9/23 for TTE and 5/11 episodes for TEE). Importantly, TEE appeared to 
have limited additional diagnostic value as a vegetation was only visible in 1 patient, in which 
it had not been seen by TTE before. This is supported by McElhinney et.al., where the 
Melody® valve was well visualized in only 5/18 patients on TEE (17).  
To overcome these problems, extended imaging modalities can be indicated to enable the 
diagnosis of definite IE. PET-CT, included as a possible imaging modality in the 2015 ESC 
modified diagnostic criteria, showed inflammation at the Melody® valve in 2 patients in whom 
no vegetations could be visualized by TTE, thereby allowing for the diagnosis of definite IE. 
PET-CT has been of confirmed value in prosthetic valve IE, not in native IE (22, 23). Pizzi 
et.al. demonstrated the diagnostic value of PET-CTA in CHD patients with IE, especially also 
visualizing abscesses and pseudoaneurysms important for treatment decisions (21, 24). 
However, an intrinsic FDG uptake in non-biological material as Dacron® or Teflon® or in 
other present surgical adhesives in close proximity to the infected biological material has to 
be considered and could limit the sensitivity of the PET-CTA (22, 24).  
Next to the added diagnostic value of PET-CT in prosthetic valve IE, recent experience 
supports the use of intracardiac echocardiography (25, 26). Despite the need of an invasive 
procedure, intracardiac echocardiography provides clear visualization of vegetations and 
potentially enables the diagnosis of definite IE (11, 17).  
Additionally, we observed a severe pulmonary stenosis in 7 patients at presentation. A mild 
residual obstruction is not uncommon after PPVI and can therefore not be considered a 
specific indicator of IE (18). However, a suddenly developed increased pressure gradient 
over the RVOT at the time of IE presentation is found as a valuable criterion to diagnose IE 
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(3). The diagnosis would change from possible to definite IE in 2 patients if a newly elevated 
gradient of > 30 mmHg was considered a minor criterion. In patients presenting with sepsis, 
a hyperdynamic state as a cause of an increased gradient has to be taken into account (27).  
In addition, a progressive valve failure could be masked by high cardiac output in sepsis (28). 
In our 4 patients presenting with sepsis, no signs of this pathophysiologic state has been 
observed.  
Furthermore, our data reveal the importance of the number of positive blood cultures 
concerning assessment by the Duke classification. In our cohort, in 5/23 episodes only one 
positive blood culture could be found. Three of these patients however could still be 
diagnosed with definite IE based on either pathological criteria after valve explantation or 
vegetations on TTE. Even though the Duke classification would not have changed for these 
patients, in cases where only 1 blood culture is positive next to negative imaging, no major 
criterion can be met and the diagnosis of possible IE has to be based on minor criteria alone.  
In patients after early valve explantation, in addition, histopathological findings for infection or 
a positive bacterial PCR on explanted valve tissue allow for a diagnosis of definite IE, being 
supportive in 3 of our cases.  
The minor criteria of the modified Duke classification also seem to show shortcomings for 
diagnosing definite IE in patients with a Melody® valve. Differentiation by predisposing 
factors is limited as all patients present with underlying CHD. Thereby no other predisposing 
factors, such as a possible entry-point or a previous history of IE, are taken into 
consideration as minor criteria. As fever is also frequently present, it does not help in 
discriminating cases. Immunologic phenomena remain negative due to the right-sided nature 
of IE (18). For the same reason, only pulmonary septic emboli were seen in the category of 
vascular phenomena. Visualization of pulmonary septic emboli on CT contributed to the 
diagnosis of definite IE in 2 patients with otherwise negative imaging.  
Therefore, being attentive for > 1 positive blood culture and the use of adequate additional 
imaging modalities increases the sensitivity of the actual modified Duke criteria. The addition 
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of an increased gradient to the minor criteria seems an improvement of the Duke criteria. 
This algorithm is presented in Figure 2.   
 
Predisposing factors 
In recent reports, a higher incidence of IE was found in bovine jugular vein (BJV) valves 
compared to homografts and other valve types (6, 20). Potential risk factors and pathways 
evoking IE at the conduit site are not fully elucidated yet and are discussed to be mainly 
associated to patient characteristics (male gender), immunological interactions (drug users), 
the valve endothelium (damaged or inflamed endothelium), the flow pattern (an increased 
gradient over the RVOT), tissue factors (fixation and preparation of the graft tissue) and 
thrombogenicity (discontinuation of aspirin administration). Currently, in-vitro studies showed 
that the BJV tissue itself is not more prone for bacterial adhesion than e.g. homograft tissue 
(29). Interestingly, non-infected RVOT conduits revealed fibrin deposition in the valve sinus, 
which could act as a preferred matrix for bacterial adhesion upon bacteremia (30). Further 
research should elucidate further possible relevant pathogenic factors, as tissue origin and 
the phenotype of endothelial cells repopulating the graft tissue (7, 13). A residual gradient 
after PPVI causing turbulent flow patterns has been identified by Nordmeyer et. al. as a risk 
factor for IE with an increased risk by every 5 mmHg (3). McElhinney et.al. and others stated 
that the post-procedural RVOT gradient after PPVI correlates with the risk of IE (5, 17, 31). 
These important findings have led to the intention to implant the Melody® valve at the 
largest, possible diameter, balancing this decision with the risk of coronary compression and 
conduit rupture. The discontinuation of aspirin has been discussed to be associated with IE, 
yet there is no proven evidence as only few centers give preventive aspirin after PPVI (4, 
32). Besides one, none of our patients received anti-platelet prophylaxis, as this strategy is 
currently only followed in one of our centers. An increased thrombogenicity plays a role, 
especially in S. aureus infections, where the bacterium interferes with platelet activation (33). 
In this context, a benefit of anti-platelet agents as aspirin or ticagrelor in the prevention of S. 
aureus IE is discussed and might be a valuable future preventive strategy as antibiotic 
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prophylaxis is timewise limited to medical procedures (12, 34). The recently reported anti-
bactericidal effect of ticagrelor might open new additional perspectives (34).  
In more than half of our patients, a possible dental or cutaneous entry-point could be 
identified and especially striking, even an orthodontic treatment was found as a possible 
causal procedure. Therefore, our data support evidence that the patient’s hygiene and 
prevention measures are an extremely important issue. Investigations on adolescents with 
CHD found the striking result that they have insufficient knowledge of risk factors for IE, its 
symptoms and the need for medical advice before starting antibiotics (35). In general, a poor 
dental hygiene is a known risk factor for IE and plaque formation may lead to gingivitis risking 
to result in bacteremia. The incidence of bacteremia from tooth brushing and other daily 
activities on an annual basis is thought to exceed that of dental procedures by far. This 
strengthens the positive impact of a good daily oral hygiene which is therefore addressed in 
the actual recommendations of the European Society of Cardiology (ESC) and the American 
Heart Association (AHA) (12). Atopic dermatitis is less well studied as a risk factor for IE, but 
various case reports describe an association, especially with S. aureus IE (13). Therefore, 
we suggest that structured information should be provided to the general practitioners, 
dentists and patients about the increased risk for IE, preventable risk factors and how to 
respond when IE is suspected. A dental checkup before PPVI should be recommended and 
adding risk factors as trans-mucosal piercings should be avoided. A dental and general 
health care check-up could be secured, if provided by the cardiac centers. Every episode of 
fever should be investigated by a physician and blood cultures must be taken before starting 
antibiotics in this patient group.  
 
LIMITATIONS 
This is a retrospective analysis including a limited number of patients. Due to the incidence of 
IE after PPVI, multi-national, prospective surveys would be beneficial in the future.  
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CONCLUSIONS 
IE remains an important complication after Melody® valve PPVI in three Belgian tertiary 
referral centers with a relevant need of re-interventions, especially in S. aureus IE.  The 
choice of percutaneous or surgical re-intervention and the respective outcome needs further 
evaluation. PET-CT, intracardiac echocardiography and assessing the development of a new 
pressure gradient could improve the diagnostic performance of the modified Duke criteria. 
Structured education of patients and physicians on hygiene measures and IE associated 
issues is essential for an improvement in IE prevention and diagnosis in this patient group. 
Further investigations to elucidate the potential benefit of anti-platelet drugs in IE prevention 
could contribute towards new pharmacological strategies, as the effect of antibiotic 
prophylaxis seems limited.  
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FIGURE LEGENDS 
Figure 1: Infective endocarditis  
1A shows the occurrence of Infective endocarditis over time. The cumulative number of 
patients receiving a Melody© valve in the three centers over time is presented (grey 
columns). In black, patients diagnosed with IE are indicated.  
1B shows the proportion of the underlying microorganisms. CNS = coagulase negative 
staphylococci, sp. = species, CN = culture negative. 
 
Figure 2: Algorithm for suspected infective endocarditis after percutaneous 
pulmonary valve implantation 
Suggested strategy in case of suspected infective endocarditis (IE) in cases where the Duke 
classification allows only a possible diagnosis. Taking > 2 blood cultures before the start of 
antibiotic treatment is of importance and additional imaging could allow the visualization of 
vegetations when transthoracic echocardiography (TTE) or transesophageal 
echocardiography (TEE) fails. 18 FDG-positron emission tomography (PET/CT) and the 
combination with magnetic resonance imaging (MRI), intracardiac echography (ECHO) or 
single photon emission computed tomography (SPECT/CT) might allow to make a definite IE 
diagnosis based on improved imaging. An increased Doppler gradient could count as a 
positive minor criteria.       
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IE = infective endocarditis, PPVI = Percutaneous pulmonary valve implantation, RVOT = right ventricle outflow tract, n = 
number of patients. CI = confidence interval. Hazard ratios (HR) are calculated from a multivariate analysis. IE patients were 
analyzed in comparison to non-IE patients.   
 
  
Patients without IE IE 
(n = 22) (n = 218)
n or median (range or %) n or median (range or %) P-value HR (95% CI)
Gender (male/female) 19/3 139/79 0.033 3.602 (1.063-12.204)
Age at PPVI (years) 14.7 (7-43.5) 17.2 (3.5-81.6) 0.077 0.959 (0.013 -1.007)
Weight (kg) 50.8 (23-91) 55.0 (15-147) ns (0.588)
Diagnosis  ns (0.101)
  Tetralogy of Fallot 10 (45%) 117 (54%)
  Truncus arteriosus 5 (23%) 16 (7%)
  Pulmonary stenosis / atresia 0 28 (13%)
  Post Rastelli procedure 4 (18%) 19 (9%)
  Post Ross procedure 3 (14%) 38 (17%)
RVOT conduit type ns (0.697)
  Native RVOT 4 (18%) 63 (29%)
  Homograft 16 73%) 137 (63%)
  Bovine heterograft (Contegra®) 2 (9%) 27 (12%)
  Bioprosthesis 0 9 (4%)
 Melody® 0 3 (1%)
Indication for PPVI ns (0.215)
  Stenosis 14 (64%) 97 (45%)
  Insufficiency 4 (18%) 70 (32%)
  Mixed 4 (18%) 51 (23%)
Final diameter Melody® (mm) 22 (16-22) 22 (18-24) ns (0.303)
Table 1  Characteristics of all patients 
                                                                                                 IE patients                            
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Table 2: Patient characteristics at IE presentation 
  n or median (range or %) 
  Age at IE (years) 17.9 (8.2 - 45.9) 
Time from PPVI to IE episode (years) 2.4 (0.7 - 8.0) 
Presenting symptoms 
 
  Fever or subfebrility 20 (87 %) 
  Effort intolerance or fatigue 10 (43%) 
  Sepsis 4 (17%) 
Predisposing factors and possible entry-point 
  Dental hygiene or procedure 9 (39%) 
  Cutaneous 8 (35%) 
Previous episode of IE 2 (9%) 
Positive blood culture 
 
  Multiple 17 (74%) 
  Single 5 (22%) 
  None 1 (4%) 
Maximal RVOT gradient at IE  
  0 - 39 mm Hg 12 (52%) 
  40 - 60 mm Hg 4 (17%) 
  > 60 mm Hg 7 (30%) 
Increase in RVOT gradient at IE  
  ≤ 10 mm Hg 11 (48%) 
  11 - 30 mm Hg 4 (17%) 
  31 - 50 mm Hg 4 (17%) 
  > 50 mm Hg 4 (17%) 
  
IE = infective endocarditis, PPVI = Percutaneous pulmonary valve implantation, RVOT =  
right ventricular outflow tract, n = number of patients, % of all 23 IE episodes.  
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IE = infective endocarditis, TTE = transthoracic echocardio- 
graphy, TEE = transesophageal echocardiography,  
CHD = congenital heart disease, n = number of patients 
 
  
Table 3: Duke criteria
n
Definite IE 15 (65%) 
Possible IE  8  ( 35%)
Pathological criteria  3  (13%)
Major clinical criteria
Blood culture positive (≥ 2) 17 (74%)
Positive imaging 13 (57%)
  TTE and TEE 10 (43%)
  PET-CT  5  (22%)
  Intracardiac echocardiography  1  (4%)
Minor clinical criteria
CHD 23 (100%)
Fever > 38°C 21 (91%)
Vascular phenomena
  Pulmonary septic embolism  8  (35%)
Minor microbiologic criteria  5  (22%)
Immunological phenomena  0  (0%)
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 Table 4: Treatment and outcome   
 n 
  
Antibiotic treatment (6 weeks) 23 
Early interventions  9   (39%) 
  ICU admission  0 
  Urgent transcatheter treatment  
  Emergency surgery 
 2   (8%) 
 0 
  Urgent surgery  0 
  Early elective surgery  4   (17%) 
  Delayed balloon valvuloplasty  1   (4%) 
  Delayed surgery  2   (8%) 
  Late interventions  6   (26%) 
  Balloon valvuloplasty  1   (4%) 
  Second TPV  4   (17%) 
  Late surgery  1   (4%) 
  
Total RVOT reinterventions after IE 13/22 (59%) 
Death-related to IE 0/22 
_____________________________________________________________________________________________________________________________________________________________________________ 
ICU = Intensive care unit, TPV = transcatheter pulmonary valve,  
RVOT = right ventricle outflow tract, IE = infective endocarditis, 
n = number of patients 
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Highlights 
 IE after PPVI is associated with a high requirement for re-intervention.  
 Sensitivity of the Duke criteria can be improved by additional imaging methods. 
 An otherwise not explainable increase in RVOT gradient seems a valuable criterion.  
 Patients’ knowledge of IE is essential to prevent diagnostic delay and morbidity.  
 Improving patients’ and physicians’ knowledge on general and oral health care seems 
essential in IE prevention.   
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